QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) An erratum has been published Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Komuro, S. Articles by Kanamaru, H. Search for Related Content PubMed PubMed Citation Articles by Komuro, S. Articles by Kanamaru, H.

SHORT COMMUNICATION

DISPOSITION AND METABOLISM OF F₆-1,25(OH)₂ VITAMIN D₃ AND 1,25(OH)₂ VITAMIN D₃ IN THE PARATHYROID GLANDS OF RATS DOSED WITH TRITIUM-LABELED COMPOUNDS

	Abstract

Top Abstract Materials and Methods Results and Discussion References

 
26,26,26,27,27,27-Hexafluoro-1,25(OH)₂ vitamin D₃, a hexafluorinated analog of 1,25(OH)₂ vitamin D₃, has been reported to be several times more potent than the parent compound with respect to some vitamin D actions. The reason for enhanced biological activity in the bones, kidneys, and small intestine appears to be related to F₆-1,25(OH)₂ vitamin D₃ metabolism to ST-232 (26,26,26,27,27,27-hexafluoro-1,23S,25-trihydroxyvitamin D₃), a bioactive 23S-hydroxylated form that is resistant to further metabolism. We compared the disposition and metabolism of [1ß-³H]F₆-1,25(OH)₂ vitamin D₃ and [1ß-³H]1,25(OH)₂ vitamin D₃ in parathyroid glands of rats intravenously administered with labeled compounds at a dose of 10 µg/kg. In the [1ß-³H]F₆-1,25(OH)₂ vitamin D₃-dosed group, radioactivity was highly detected in the kidneys, parathyroid glands, and the small intestine. The radioactivity in the parathyroid glands remained high until 48 h postdosing, with values of 2.5, 8.4, and 14.6 times higher at 6, 24, and 48 h postdosing than after dosing with [1ß-³H] 1,25(OH)₂ vitamin D₃. In the group given [1ß-³H]F₆-1,25(OH)₂ vitamin D₃, the unchanged compound was mainly detected with a small amount of ST-232 at 6 h postdosing. At the 24- and 48-h time points, over half of the radioactivity was observed as ST-232, and additionally, ST-233, the 23-oxo form, accounted for a small amount at the 48-h time point. The present study demonstrated local retention of [1ß-³H]F₆-1,25(OH)₂ vitamin D₃ and the bioactive metabolite ST-232 in parathyroid glands after intravenous administration. The findings may indicate one of the reasons for the higher potency of F₆-1,25(OH)₂ vitamin D₃ than 1,25(OH)₂ vitamin D₃ in parathyroid.

26,26,26,27,27,27-Hexafluoro-1,25(OH)₂ vitamin D₃ [F₆-1,25(OH)₂VD₃], a fluorinated derivative of 1,25(OH)₂VD₃ has been reported to be several times as potent as the parent compound at increasing intestinal calcium transport and bone calcium (Tanaka et al., 1984; Kiriyama et al., 1991; Inaba et al., 1993). The inhibitory effect of F₆-1,25(OH)₂VD₃ on PTH secretion from parathyroid cells also exceeds that of the parent compound (Katsumata et al., 1996; Tsushima et al., 1996; Imanishi et al., 1999). F₆-1,25(OH)₂VD₃ has been used clinically for the treatment of secondary hyperparathyroidism in cases of chronic renal failure and for the control of hypoparathyroidism (Nakatsuka et al., 1992; Akiba et al., 1998; Inoue and Fujimi, 1998; Morii et al., 1998). The mechanism of action of 1,25(OH)₂VD₃ involves a specific intracellular receptor (vitamin D receptor, VDR), which binds 1,25(OH)₂VD₃ with a high affinity and modulates the transcription of vitamin D responsive genes in the parathyroid glands (Naveh-Many et al., 1990; Demay et al., 1992; Brown et al., 1992b, 1995; Hellman et al., 1999). F₆-1,25(OH)₂VD₃ is considered to act by the same pathway.

We earlier demonstrated that radioactivity was mainly found in the vitamin D target tissues (i.e., in the kidneys and small intestine) and is locally distributed in the methaphysis of bone in rats dosed with [1ß-³H]F₆-1,25(OH)₂VD₃ (Komuro et al., 1996b, 1998). ST-232 (26,26,26,27,27,27-hexafluoro-1,23S,25-trihydroxyvitamin D₃), a 23S-hydroxylated metabolite, accounted for the majority of the compound administered (Komuro et al., 1996a,c, 1998), and we further reported that F₆-1,25(OH)₂VD₃ can be transformed to ST-232 in the kidneys and small intestine on the basis of in vitro metabolic studies (Komuro et al., 1999). Moreover, ST-232, the main metabolite of F₆-1,25(OH)₂VD₃ in target tissues, is reported to retain biological activity (Katsumata et al., 1996), whereas the 23S-hydroxylated metabolite of 1,25(OH)₂VD₃ was a less active compound (Horst et al., 1984).

It has been demonstrated that F₆-1,25(OH)₂VD₃ is metabolized to ST-232 by rat or human mitochondrial 24-hydroxylase expressed in Escherichia coli (Hayashi et al., 1998; Sakaki et al., 2003), and we have reported that the enzyme in the small intestine is induced by F₆-1,25(OH)₂VD₃ itself (Komuro et al., 1999). These findings suggest that the enhanced biological activity of F₆-1,25(OH)₂VD₃ is due to its metabolism to the bioactive metabolite, ST-232, and its persistence as this form.

With regard to the parathyroids, Imanishi et al. (1999) reported in vitro metabolism of F₆-1,25(OH)₂VD₃ in primary cultured bovine parathyroid cells. The present study was performed to compare [1ß-³H]F₆-1,25(OH)₂VD₃ with [1ß-³H]1,25(OH)₂VD₃ with regard to the distribution and metabolism in the parathyroid glands after intravenous dosing.

	Materials and Methods

Top Abstract Materials and Methods Results and Discussion References

 
Materials. Radioactive [1ß-³H]F₆-1,25(OH)₂VD₃ (code TRQ 6721 or 8742; 640 or 555 GBq/mmol; Fig. 1) and [1ß-³H]1,25(OH)₂VD₃ (code TRQ 7362, 618 GBq/mmol; Fig. 1) were purchased from Amersham Biosciences UK, Ltd. (Little Chalfont, Buckinghamshire, UK).

View larger version (21K): [in this window] [in a new window]   FIG. 1. Chemical structures of [1ß-3H]F6-1,25(OH)2VD3, its metabolites and [1ß-3H]1,25(OH)2VD3 (*, tritium-labeled position).

Nonradioactive F₆-1,25(OH)₂VD₃ (lot no. 80201) was obtained from Sumitomo Pharmaceuticals (Osaka, Japan). Nonradioactive ST-232 [23S-hydroxy-F₆-1,25(OH)₂VD₃, lot no. 508CR001] and ST-233 [23-oxo-F₆-1,(OH)VD₃, lot no.410211], the metabolites of F₆-1,25(OH)₂VD₃ detected in the kidneys (Komuro et al., 1996a), intestine (Komuro et al., 1996a), and bones (Komuro et al., 1998) of rats dosed with [1ß-³H]F₆-1,25(OH)₂VD₃, were also obtained from Sumitomo Pharmaceuticals (Fig. 1). All other reagents and solvents were of the best grade commercially available in standard catalogs.

Animals. Fourteen-week-old male Wistar rats were purchased from Japan SLC (Shizuoka, Japan) and were used at the age of 15 weeks. During experiment 1, the rats had free access to tap water and MF laboratory food (Oriental Yeast Co., Ltd., Tokyo, Japan). During experiment 2, the rats received tap water and CRF-1 laboratory food (Oriental Yeast Co., Ltd.) ad libitum. The rats were given [1ß-³H]F₆-1,25(OH)₂VD₃ or [1ß-³H]1,25(OH)₂VD₃ at a dose of 10 µg/kg. The administration was performed intravenously in a volume of 0.5 ml/kg b.w. using ethanol/saline (1:1, v/v) as the vehicle. The dose levels were higher than those in clinical use but were chosen as a compromise to give detectable parathyroid gland levels of the test compound.

Experiment 1, Distribution Studies. At 6, 24, and 48 h postdosing, 8 to 10 rats per time point for each dose were anesthetized with diethyl ether, and blood was collected from the abdominal vein. After killing, the thyroid glands including parathyroid glands were resected, and the parathyroid glands were removed under a microscope (experiment 1: SZH, Olympus, Tokyo, Japan; experiment 2: SZ4045, Olympus). The liver, kidneys, intestine, bones, and skin were also resected, and serum was separated from blood by centrifugation. The thyroid glands excluding the parathyroid glands, kidneys, and small intestine were homogenized with similar amounts of saline. Tissues, tissue homogenates, and serum of each animal were removed for oxidation in a sample oxidizer (Tri-Carb model 387; PerkinElmer Life Sciences, Boston, MA).

Experiment 2, Metabolism Studies. The parathyroid glands of six rats were pooled and homogenized with saline using both a digital-homogenizer (Iuchi, Osaka, Japan) and a sonic-homogenizer (Sonifier 250; Branson UnltrasonicsCorporation, Danbury, CT) until no particles were observed. Homogenized samples were transferred to microtubes and extracted three times with 1 ml of ethanol. The extracts were combined and dried under a stream of nitrogen. For radioactivity profiling, the reconstituted samples were applied to high-performance liquid chromatography (HPLC) equipment. To estimate the recovery, parathyroid glands of three additional rats were pooled and treated as described above, and the extracts and the residues were dissolved with ethanol and a tissue solubilizer, NCS-2 (PerkinElmer Life Sciences), for radioactivity counting. The serum of six rats was pooled, 100-µl aliquots were filtered [Sun-prep 4(T)-HV, 0.45 mm, 4-mm i.d.; Millipore Corporation, Bedford, MA] and combined with 100 µl of saline used for washing the filter, and then the filtration samples were applied to HPLC.

The HPLC apparatus was equipped with a solvent delivery pump (L-6300; Hitachi, Tokyo, Japan), an ultraviolet detector (SPD-10A, 254 nm; Shimadzu, Kyoto, Japan), and a data-acquisition system (805 data station; Waters, Tokyo, Japan), with a reversed-phase ODS column (Sumipax ODS A-212, 5 µm, 6.0 mm i.d. x 150 mm; Sumika Chemical Analytical Service, Osaka, Japan) at a flow rate of 1.5 ml/min. The mobile phase used was acetonitrile/water/tetrahydrofuran (55:40:5, v/v/v). The effluents were collected in 20-s fractions, and the radioactivity of each fraction was measured and profiled. Identification of metabolites was performed by cochromatography with F₆-1,25(OH)₂VD_3, ST-232, and ST-233 standards. The relative proportions of metabolites were calculated from the total radioactivity of the sample in each radiochromatogram.

Radioactivity Measurements. The radioactivity of each sample was determined with a liquid scintillation spectrometer (system 387; PerkinElmer Life Sciences).

	Results and Discussion

Top Abstract Materials and Methods Results and Discussion References

 
Parathyroid, Serum, and Other Tissue Levels of Radioactivity. Data for parathyroid, serum, and other tissue levels of radioactivity 6, 24, and 48 h after single intravenous administrations of [1ß-³H]F₆-1,25(OH)₂VD₃ and [1ß-³H]1,25(OH)₂VD₃ to rats are summarized in Table 1. With [1ß-³H]F₆-1,25(OH)₂VD₃, the values at 6, 24, and 48 h postdosing were relatively constant at 73.6, 64.9, and 71.3 ng Eq/g, respectively, whereas they decreased with time in the [1ß-³H]1,25(OH)₂VD₃ case. The differences at 6, 24, and 48 h postdosing were 2.5-, 8.4-, and 14.6-fold, respectively.

View this table: [in this window] [in a new window]   TABLE 1 Tissue levels of radioactivity 6, 24, and 48 h after intravenous administration of [1ß-3H]F6-1,25(OH) 2VD3 or [1ß-3H]1,25(OH)2 VD3 at a dose of 10 µg/kg to rats

Radioactivity in the serum of rats dosed intravenously with [1ß-³H]F₆-1,25(OH)₂VD₃ was decreased with time. In the intestine and kidneys, the highest values were observed at 24 h postdosing, whereas in the other tissues, they were apparent at 6 h postdosing. The radioactivities in kidneys and intestine at 48 h postdosing were 85.7- and 20.1-fold, respectively, higher than that in serum. In the group given [1ß-³H]1,25(OH)₂VD₃ administration, the radioactivity levels in serum and tissues declined relatively rapidly, and maximum levels of radioactivity were observed at 6 h postdosing.

Metabolites in Parathyroid and Serum with [1ß-³H]F₆-1,25(OH)₂VD₃ Administration. Radio-HPLC profiles of parathyroid and serum 6, 24, and 48 h after a single intravenous administration of [1ß-³H]F₆-1,25(OH)₂VD₃ are shown in Fig. 2, and data for metabolites are summarized in Table 2. The recovery by pretreatment procedure was over 95% of total radioactivity. Therefore, the composition percentage on HPLC is very similar to that on total radioactivity. The metabolite patterns allowed clear assignment by comparison with authentic standards. At 6 h postdosing, the unchanged compound was mainly detected at about 74.2% on HPLC. At the 24- and 48-h time points, over half of the radioactivity was observed as ST-232 (50.5 and 75.0% on HPLC, respectively); then ST-233, the 23-oxo form, was additionally apparent at 48 h.

View larger version (19K): [in this window] [in a new window]   FIG. 2. HPLC profiles of parathyroid extracts of rats 6, 24, and 48 h after intravenous administration of [1ß-3H]F6-1,25(OH)2VD3 at a dose of 10 µg/kg.

View this table: [in this window] [in a new window]   TABLE 2 Composition of metabolites in parathyroid extracts and serum of rats 6, 24, and 48 h after intravenous administration of [1ß-3H]F6-1 ,25(OH)2VD3 at a dose of 10 µg/kg

The metabolite patterns of serum allowed clear assignment by comparison with authentic standards. At 6 h postdosing, the unchanged compound was mainly detected at about 90.6% on HPLC and then decreased with time. However, no metabolites were evident (Fig. 3). The large amount of radioactivity eluting at solvent front of the serum profiles seems to be tritiated water, because our previous data shows that the ratios of serum concentration of radioactivity assayed by wet method and dry method at 24 h after doing of rats was 0.51 (Komuro et al., 1996b).

View larger version (20K): [in this window] [in a new window]   FIG. 3. HPLC profiles of serum of rats 6, 24, and 48 h after intravenous administration of [1ß-3H]F6-1,25(OH)2VD3 at a dose of 10 µg/kg.

The parathyroid gland is the overall regulatory organ for general calcium homeostasis. F₆-1,25(OH)₂VD₃ is reported to have one-third the affinity of 1,25(OH)₂VD₃ for binding to vitamin D-binding protein and one-fourth for VDR, increasing blood-ionized calcium in parathyroidectomized rats to normal levels (Katsumata et al., 1996). In addition, F₆-1,25(OH)₂VD₃ administered orally was found to reduce increasing plasma PTH concentrations and PTH mRNA levels in parathyroid-thyroid tissues with therapeutic effects on aberrant bone metabolism in 5/6 nephrectomized rats at lower doses than with 1,25(OH)₂VD₃ (Tsushima et al., 1996). Based on these results, the compound was evaluated for the biological potency and the applicability for clinical control of hypoparathyroidism, secondary hyperparathyroidism, and osteodystrophy in patients with chronic renal failure at lower doses than that of 1,25(OH)₂VD₃ (Nakatsuka et al., 1992; Akiba et al., 1998; Inoue and Fujimi, 1998; Morii et al., 1998).

In the present study, to clarify the distribution of radioactivity in the parathyroid glands of rats dosed with [1ß-³H]F₆-1,25(OH)₂VD₃ or [1ß-³H]1,25(OH)₂VD₃, we separated the parathyroid glands from the thyroid glands, allowing demonstration of specific distribution and accumulation of radioactivity in the parathyroid glands. Levels of radioactivity 6, 24, and 48 h after single intravenous administration of [1ß-³H]F₆-1,25(OH)₂VD₃ were consistently higher in the parathyroid glands than in the serum, with a distribution pattern that is similar to that in kidneys and small intestine, the target organs of this compound. In contrast, a marked decrease with time was observed for the [1ß-³H]1,25(OH)₂VD₃ case. The main form of [1ß-³H]F₆-1,25(OH)₂VD₃ in parathyroid glands at 6 h postdosing was determined to be the unchanged compound, whereas at 24 and 48 h postdosing, ST-232, a biologically active metabolite, predominated. In serum, the unchanged compound was mainly detected at 6 h postdosing and then decreased with time, but no metabolites were detected. This again demonstrates similarity for the parathyroid glands with the kidneys, small intestine, and bone, rather than for the serum.

Parathyroid glands are reported to contain VDR (Naveh-Many et al., 1990; Brown et al., 1992b, 1995; Demay et al., 1992; Hellman et al., 1999), and therefore the observed distribution of radioactivity may reflect binding of [1ß-³H]F₆-1,25(OH)₂VD₃ and [1ß-³H]1,25(OH)₂VD₃. Brown et al. (1992a, 1999) earlier reported that in parathyroid cells, as in other target tissues, 1,25(OH)₂VD₃ was degraded by side chain oxidation, suggesting that the inducible 24-hydroxylase is responsible. Recently, reverse-transcription polymerase chain reaction and immunohistochemical analyses showed expression of 1-hydroxylase in both normal and pathological parathyroid tissue, and the findings imply that in addition to feedback control by circulating 1,25(OH)₂VD₃ levels, parathyroid cells may also be influenced by local 1-hydroxylase activity with possible growth-regulatory effects (Segersten et al., 2002). Under basal conditions, a non-small cell lung carcinoma expressed only CYP1 and showed 1-hydroxylase enzyme activity, but when treated with 1,25(OH)₂VD₃, it began to express CYP24 and to exhibit 24-hydroxylase enzyme activity (Jones et al., 1999). Although the existence of 24-hydroxylase in the parathyroid glands remains to be confirmed, a similar situation might also prevail in this site.

In conclusion, the present study demonstrated local retention of [1ß-³H]F₆-1,25(OH)₂VD₃ and the bioactive metabolite ST-232 in parathyroid glands after intravenous administration. The findings may indicate that one of the reasons for the higher potency of F₆-1,25(OH)₂VD₃ than 1,25(OH)₂VD₃ in parathyroid glands is linked to differences in distribution and metabolism.

Setsuko Komuro
Masayuki Sato²
Hiroshi Kanamaru

Environmental Health Science Laboratory, Sumitomo Chemical Co. Ltd., Osaka, Japan

	Acknowledgments

 
We thank K. Takahashi and M. Ikeda, staff of the Research Laboratory of Sumitomo Pharmaceuticals, for synthesizing the authentic standards. We also express our appreciation to J. Iwatani, S. Ochiai, and S. Imai for generous assistance, and to S. Kitajima of Panapharm laboratories for kind help with the distribution studies.

	Footnotes

 
¹ Abbreviations used are: 1,25(OH)₂VD₃, 1,25-dihydroxyvitamin D₃; PTH, parathyroid hormone; F₆-1,25(OH)₂VD₃, 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D₃; VDR, vitamin D receptor; ST-232 or 23S-hydroxy-F₆-1,25(OH)₂VD₃, 26,26,26,27,27,27-hexafluoro-1,23S,25-trihydroxyvitamin D₃; ST-233 or 23-oxo-F₆-1,(OH)VD₃, 23oxo-26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D₃; HPLC, high-performance liquid chromatography.

² Present address: Sumitomo Chemical Deutschland GmbH, Dusseldorf, Germany.

Address correspondence to: Setsuko Komuro, Environmental Health Science Laboratory, Sumitomo Chemical Co. Ltd., Osaka, Japan, 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka, 554-8558, Japan. E-mail: komuro{at}sc.sumitomo-chem.co.jp

	References

Top Abstract Materials and Methods Results and Discussion References

 


Akiba T, Marumo F, Owada A, Kurihara S, Inoue A, Chida Y, Ando R, Shinoda T, Ishida Y, and Ohashi Y (1998) Controlled trial of falecalcitoriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 32: 238–246.[Medline]

Brown AJ, Berkoben M, Ritter C, Kubodera N, Nishii Y, and Slatopolsky E (1992a) Metabolism of 22-oxacalcitriol by a vitamin D-inducible pathway in cultured parathyroid cells. Biochem Biophys Res Commun 189: 759–764.[CrossRef][Medline]

Brown AJ, Berkoben M, Ritter C, and Slatopolsky E (1992b) Binding and metabolism of 1,25-dihydroxyvitamin D₃ in cultured bovine parathyroid cells. Endocrinology 30: 276–281.

Brown AJ, Ritter C, Slatopolsky E, Muralidharan KR, Okamura WH, and Reddy GS (1999) 1,25-Dihydroxy 3-epi-vitamin D₃, a natural metabolite of 1,25-dihydroxyvitamin D₃, is a potent suppressor of parathyroid hormone secretion. J Cell Biochem 73: 106–113.[CrossRef][Medline]

Brown AJ, Zhong M, Finch J, Ritter C, and Slatopolsky E (1995) The roles of calcium and 1,25-dihydroxyvitamin D₃ in the regulation of vitamin D receptor expression by rat parathyroid gland. Endocrinology 136: 1419–1425.[Abstract]

Cantly LK, Russell J, Lettieri D, and Sherwood LM (1985) 1,25-Dyhydroxyvitamin D₃ suppress parathyroid hormone secretion from bovine parathyroid cells in tissue culture. Endocrinology 117: 2114–2119.[Abstract]

Chertow BS, Baylink DJ, Wergdeal JE, Sherrard DJ, and Norman QW (1975) Decrease in serum immunoreactive parathyroid hormone in rats and in parathyroid hormone secretion in vitro by 1,25-dihydroxycholecalciferol. J Clin Investig 56: 668–678.

Demay MB, Kiernan MS, DeLuca HF, and Kronenberg HM (1992) Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D₃ receptor and mediated transcriptional repression in response to 1,25-dihydroxyvitamin D₃. Proc Natl Acad Sci USA 89: 8097–8101.[Abstract/Free Full Text]

Hayashi H, Akiyoshi-Shibata M, Sakaki T, and Yabusaki Y (1998) Rat CYP24 catalyzes 23S-hydroxylation of 26,26,26,27,27,27-hexafluorocalcitriol in vitro. Xenobiotica 28: 457–463.[CrossRef][Medline]

Hellman P, Liu W, Torma H, and Akerstrom G (1999) Vitamin D and retinoids in parathyroid glands. Int J Mol Med 3: 355–361.[Medline]

Horst RL, Wovkulich PM, Baggiolioni EG, Uskokovic MR, Engstrom GW, and Napoli JL (1984) (23S)-1,23,25-Trihydroxyvitamn D₃: its biologic activity and role in 1, 25-dihydroxyvitamin D₃-26,23-lactone biosynthesis. Biochemistry 23: 3973–3979.[CrossRef][Medline]

Imanishi Y, Inaba M, Seki H, Koyama H, Nishizawa Y, Morii H, and Otani S (1999) Increased biological potency of hexafluorinated analogs of 1,25-dihydroxyvitamin D₃ on bovine parathyroid cells. J Steroid Biochem Mol Biol 70: 243–248.[CrossRef][Medline]

Inaba M, Okuno S, Nishizawa Y, Imanishi Y, Katsumata T, Sugata I, and Morii H (1993) Effect of substituting fluorine for hydrogen at C-26 and C-27 on the side chain of 1,25-dihydroxyvitamin D₃. Biochem Pharmacol 45: 2331–2336.[CrossRef][Medline]

Inoue S and Fujimi S (1998) Efficacy and safety of long term oral falecalcitriol treatment in patients with renal osteodystrophy. J Bone Miner Metab 16: 44–54.[CrossRef]

Jones G, Ramshaw H, Zhang A, Cook R, Byford V, White J, and Petkovich M (1999) Expression and activity of vitamin D-metabolizing cytochrome P450s (CYP1alpha and CYP24) in human nonsmall cell lung carcinomas. Endocrinology 140: 3303–3310.[Abstract/Free Full Text]

Katsumata T, Ishibashi E, Tanaka T, and Nakatsuka M (1996) Biological activity of falecalcitriol. Kiso to Rinsho 30: 2955–2962.

Kiriyama T, Okamoto S, Ejima E, Kurihara N, Haketa Y, Ito N, Izumi M, Kumegawa M, and Nagataki S (1991) Effect of a highly potent fluoro analog of 1,25-dihydroxyvitamin D₃ on human bone-derived cells. Endocrinology 128: 81–86.[Abstract]

Komuro S, Kanamaru H, Nakatsuka I, and Yoshitake A (1996a) Disposition and metabolism of falecalcitriol (2) metabolism after a single administration of ³H-falecalcitriol in rats. Xenobio Metab Dispos 11: 518–529.

Komuro S, Kanamaru H, Nakatsuka I, and Yoshitake A (1998) Distribution and metabolism of F₆-1, 25(OH)₂ vitamin D₃ and 1, 25(OH)₂ vitamin D₃ in the bones of rats dosed with tritium labeled compounds. Steroids 63: 505–510.[CrossRef][Medline]

Komuro S, Kanamaru H, Nakatsuka I, Yoshitake A, Ishizaki M, Nemoto H, Ueda K, Ebine H, Ninomiya S, and Esumi Y (1996b) Disposition and metabolism of falecalcitriol (1) absorption, distribution and excretion after a single oral administration of ³H-falecalcitriol in rats. Xenobio Metab Dispos 11: 505–517.

Komuro S, Nakatsuka I, Ishizaki M, Nemoto H, Gunzi S, Ninomiya S, and Esumi Y (1996c) Disposition and metabolism of falecalcitriol (The 11^th Report)–Absorption, distribution, metabolism and excretion after a single administration of ³H-falecalcitriol in dogs–. Kiso to Rinsho 30: 2915–2932.

Komuro S, Sato M, Kanamaru H, Kaneko H, Nakatsuka I, and Yoshitake A (1999) In vivo and in vitro pharmacokinetics and metabolism studies of 26,26,26,27,27,27-F₆-1,25(OH)₂ vitamin D₃ (Falecalcitriol) in rats: induction of vitaminD₃-24-hydroxylase (CYP24) responsible for 23S-hydroxylation in target tissues causes a drop in serum levels. Xenobiotica 29: 603–613.[CrossRef][Medline]

Mayer GP and Hurst JG (1978) Sigmoidal relationship between parathyroid hormone secretion rate and plasma calcium concentration in calves. Endocrinology 102: 1036–1042.[Abstract]

Morii H, Ogura Y, Koshikawa S, Mimura N, Suzuki M, Kurokawa K, Marumo F, Kawaguchi Y, Maeda K, Nishizawa Y, et al. (1998) Efficacy and safety of oral farecalcitriol in reducing parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. J Bone Miner Metab 16: 34–43.[CrossRef]

Nakatsuka K, Imanishi Y, Morishima Y, Sekiya K, Sasao K, Miki T, Nishizawa Y, Katsumata T, Nagata A, Murakawa S, and Morii H (1992) Biological potency of a fluorinated vitamin D analogue in hyperparathyroidism. Bone Miner 16: 73–81.[CrossRef][Medline]

Naveh-Many T, Marx R, Keshet E, Pike JW, and Silver J (1990) Regulation of 1,25-dihydroxyvitamin D₃ receptor gene expression by 1,25-dihydroxyvitamin D₃ in the parathyroid in vivo. J Clin Invesitig 86: 1968–1975.

Russell J, Lettiere D, and Sherwood LM (1986) Direct regulation by calcium of cytoplasmic messenger ribonucleic acid coding for preproparathyroid hormone in isolated bovine parathyroid cells. J Clin Investig 72: 1851–1855.

Sakaki T, Sawada N, Abe D, Komai K, Shiozawa S, Nonaka Y, Nakagawa K, Okano T, Ohta M, and Inouye K (2003) Metabolism of 26,26,26,27,27,27-F₆-1alpha,25-dihydroxyvitamin D₃ by CYP24: species-based difference between humans and rats. Biochem Pharmacol 65: 1957–1965.[CrossRef][Medline]

Segersten U, Correa P, Hewison M, Hellman P, Dralle H, Carling T, Akerstrom G, and Westin G (2002) 25-Hydroxyvitamin D₃-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab 87: 2967–2972.[Abstract/Free Full Text]

Silver J, Naveh-Many T, Mayer H, Schmeizer HJ, and Popovtzer MM (1986) Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Investig 78: 1296–1301.

Silver J, Russel J, and Sherwood LM (1985) Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cell. Proc Natl Acad Sci USA 82: 4270–4273.[Abstract/Free Full Text]

Tanaka Y, Deluca HF, Kobayashi Y, and Ikekawa N (1984) 26,26,26,27,27,27-Hexafluoro-1,25-dihydroxyvitamin D₃: a highly potent, long-lasting analog of 1,25-dihydroxyvitamin D₃. Arch Biochem Biophys 229: 348–354.[CrossRef][Medline]

Tsushima N, Katsumata T, Ishibashi E, Negoro T, and Nakatsuka M (1996) Therapeutic effects of falecalcitriol on secondary hyperparathyroidism and osteodystrophy in 5/6 nephrectomized rats. Kiso to Rinsho 30: 2963–2974.

This article has been cited by other articles:

				N. Kasai, T. Sakaki, R. Shinkyo, S.-i. Ikushiro, T. Iyanagi, M. Ohta, and K. Inouye METABOLISM OF 26,26,26,27,27,27-F6-1{alpha},23S,25-TRIHYDROXYVITAMIN D3 BY HUMAN UDP-GLUCURONOSYLTRANSFERASE 1A3* Drug Metab. Dispos., January 1, 2005; 33(1): 102 - 107. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) An erratum has been published Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Komuro, S. Articles by Kanamaru, H. Search for Related Content PubMed PubMed Citation Articles by Komuro, S. Articles by Kanamaru, H.